BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-162@pharmaconomics
DTSTAMP:20260707T015314Z
DTSTART;VALUE=DATE:20261114
DTEND;VALUE=DATE:20261115
SUMMARY:SMMT PDUFA — ivonescimab
DESCRIPTION:The FDA's approval decision on ivonescimab for EGFR-mutated locally advanced or metastatic non-squamous NSCLC post‑TKI therapy is due Nov 14\, 2026. A green light opens the market\; a complete response letter (CRL) usually sinks the stock.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1599298/000159929826000004/a2026_prx0112xblasubmiss.htm\n\nTrack it: https://pharmaconomics.com/e/162
URL:https://pharmaconomics.com/e/162
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:SMMT catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR